Alkermes plc (ALKS)
NASDAQ: ALKS · IEX Real-Time Price · USD
27.88
-0.16 (-0.57%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Alkermes Revenue
Alkermes had revenue of $399.13M in the quarter ending June 30, 2024, a decrease of -35.35%. This brings the company's revenue in the last twelve months to $1.51B, up 3.14% year-over-year. In the year 2023, Alkermes had annual revenue of $1.66B with 49.61% growth.
Revenue (ttm)
$1.51B
Revenue Growth
+3.14%
P/S Ratio
3.13
Revenue / Employee
$718,055
Employees
2,100
Market Cap
4.72B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.66B | 551.61M | 49.61% |
Dec 31, 2022 | 1.11B | -61.96M | -5.28% |
Dec 31, 2021 | 1.17B | 134.99M | 13.00% |
Dec 31, 2020 | 1.04B | -132.19M | -11.29% |
Dec 31, 2019 | 1.17B | 76.67M | 7.01% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
RadNet | 1.66B |
Integer Holdings | 1.63B |
Haemonetics | 1.31B |
Inspire Medical Systems | 660.91M |
Apellis Pharmaceuticals | 524.07M |
TransMedics Group | 296.92M |
CRISPR Therapeutics AG | 271.71M |
Avidity Biosciences | 10.87M |
ALKS News
- 2 days ago - Alkermes plc Reports Second Quarter 2024 Financial Results - PRNewsWire
- 9 days ago - Alkermes to Report Second Quarter Financial Results on July 24, 2024 - PRNewsWire
- 7 weeks ago - Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024 - PRNewsWire
- 2 months ago - Alkermes to Participate in Two Upcoming Investor Conferences - PRNewsWire
- 2 months ago - Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024 - PRNewsWire
- 2 months ago - Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences - PRNewsWire
- 3 months ago - Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk - PRNewsWire
- 3 months ago - Alkermes plc Reports First Quarter 2024 Financial Results - PRNewsWire